9th Fragment-based Drug Discovery Meeting
9th RSC-BMCS Fragment-based Drug Discovery Meeting
Monday 4th – Tuesday 5th March, 2024
Hinxton Hall, Wellcome Genome Campus, Cambridge
Important links and downloads
Twitter hashtag – #Fragments24
The aim of the 9th RSC-BMCS Fragment-based Drug Discovery meeting will be to continue the focus on case studies in Fragment-based Drug Discovery that have delivered compounds to late stage medicinal chemistry, preclinical or clinical programmes. The Fragment series was started in 2007 and continues with this theme in having over three-quarters of the presentations focused on case studies. This will be complemented by technology progress in high concentration, NMR, SPR and X-ray screening.
Who should attend
This conference is suitable for scientists including chemists, biophysicists, structural biologists, etc., with either existing experience of fragments or wanting to learn about this exciting approach to drug discovery. This international meeting attracts delegates from the UK, several mainland European counties, as well as from the USA, Japan, China and South Korea.
Want to become a member?
To join the RSC in order to qualify for discounted registration fees at all RSC, please follow this RSC link.
Emma Grant, GSK
Iva Lukac, Charnwood Molecular
Darryl McConnell, Boehringer Ingelheim
Gordon Saxty, Fidelta d.o.o. (Chair)
Marianne Schimpl, AstraZeneca
Mary Wheldon, University of Dundee (Treasurer)
Alison Woolford, Astex Pharmaceuticals
Hg3 Conferences Ltd
+44 (0)1423 529333